◎ Sugi Atlas

Atlas / Drug / Oxytocin

Oxytocin

drug
On this page

Also known as Alpha-hypophamineEndopituitrinaIntertocine sOxitocinaOxytocineOxytocinumOrasthinPitocinSyntocinonSyntometrineTNX-1900TNX1900TTA-121Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2SID50112429

Summary

Oxytocin (CHEMBL395429) is an approved protein vasodilator agent (ATC H01BB02) targeting AVPR1A, AVPR1B, and AVPR2; indicated across 53 conditions including autism spectrum disorder and dystocia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: H01BB02
  • Targets: 4 (AVPR1A, AVPR1B, AVPR2…)
  • Indications: 53 conditions
  • Clinical trials: 504
  • Chemistry: 1007.2 Da · C43H66N12O12S2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL395429
NameOxytocin
TypeProtein
Max phase4
FDA approvedyes
PubChem CID439302
ChEBICHEBI:7872
ATCH01BB02
Molecular formulaC43H66N12O12S2
Molecular weight1007.2
InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N

SMILES: CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N

IUPAC name: (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide

ChEBI definition: A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.

Pharmacological roles (ChEBI): oxytocic, vasodilator agent.

Also known as: Alpha-hypophamine, Endopituitrina, Intertocine s, Oxitocina, Oxytocin, Oxytocine, Oxytocinum, Orasthin, Pitocin, Syntocinon, Syntometrine, TNX-1900

Parent form; salt/anhydrous children: CHEMBL3185709

Patent coverage: 13,471 distinct patent families (41,727 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 41,716 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
AVPR1AV1A receptorFull agonist8.34.6%P37288
AVPR1BV1B receptorFull agonist70.4%P47901
AVPR2V2 receptorFull agonist6.80%P30518
OXTROT receptorFull agonist9.60.1%P30559

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Vasopressin V2 receptor, Vasopressin V1a receptor, Vasopressin V1b receptor, Oxytocin receptor, Oxytocin receptor, Vasopressin V2 receptor, Oxytocin receptor.

Bioactivity

ChEMBL activities: 63 potent at pChembl ≥ 5 of 63 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
OXTR11EC500.01nMCHEMBL_ACT_19206189
OXTR10.4EC500.04nMCHEMBL_ACT_16614744
OXTR10.4EC500.04nMCHEMBL_ACT_18480017
AVPR1A9.74EC500.18nMCHEMBL_ACT_19193949
AVPR1A9.72EC500.19nMCHEMBL_ACT_19206198
AVPR1B9.7EC500.2nMCHEMBL_ACT_19193956
OXTR9.52EC500.3nMCHEMBL_ACT_18285583
OXTR9.36Ki0.44nMCHEMBL_ACT_16614788
OXTR9.24Ki0.58nMCHEMBL_ACT_19206180
OXTR9.15EC500.7nMCHEMBL_ACT_18561472
OXTR9.1Ki0.8nMCHEMBL_ACT_1075628
OXTR9.1Ki0.79nMCHEMBL_ACT_15213897
OXTR9.1Ki0.79nMCHEMBL_ACT_15213916
OXTR9.1Ki0.8nMCHEMBL_ACT_16472260
OXTR9.1Ki0.79nMCHEMBL_ACT_5119966
P705369.05Ki0.89nMCHEMBL_ACT_318378
OXTR8.92Ki1.2nMCHEMBL_ACT_18285565
OXTR8.89EC501.28nMCHEMBL_ACT_18929257
AVPR1A8.82EC501.5nMCHEMBL_ACT_18084981
P705368.77Ki1.7nMCHEMBL_ACT_739235
P979268.7EC502nMCHEMBL_ACT_18561474
OXTR8.68EC502.1nMCHEMBL_ACT_19474030
OXTR8.64EC502.3nMCHEMBL_ACT_15001074
OXTR8.64EC502.29nMCHEMBL_ACT_18929236
OXTR8.64EC502.3nMCHEMBL_ACT_24981425
OXTR8.61EC502.46nMCHEMBL_ACT_25663336
OXTR8.57IC502.7nMCHEMBL_ACT_1945723
OXTR8.52EC503nMCHEMBL_ACT_16472262
OXTR8.3EC505nMCHEMBL_ACT_15213910
AVPR1A8.24EC505.8nMCHEMBL_ACT_18085049

Target pathways

Aggregated over 4 target gene(s): AVPR1A, AVPR1B, AVPR2, OXTR.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
Vasopressin-like receptors4AVPR1A, AVPR1B, AVPR2, OXTR
G alpha (q) signalling events3AVPR1A, AVPR1B, OXTR
Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)2AVPR1A, AVPR1B
G alpha (s) signalling events1AVPR2
Vasopressin regulates renal water homeostasis via Aquaporins1AVPR2
Cargo recognition for clathrin-mediated endocytosis1AVPR2
Clathrin-mediated endocytosis1AVPR2
Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)1AVPR2

Dominant GO biological processes

GO termTargets
regulation of systemic arterial blood pressure by vasopressin4
G protein-coupled receptor signaling pathway4
cellular response to hormone stimulus4
positive regulation of vasoconstriction4
signal transduction4
positive regulation of blood pressure3
positive regulation of systemic arterial blood pressure2
positive regulation of cytosolic calcium ion concentration2
positive regulation of cell population proliferation2
telencephalon development2
transport across blood-brain barrier2
regulation of blood pressure2
maternal aggressive behavior1
generation of precursor metabolites and energy1
negative regulation of female receptivity1

Indications & clinical

Indications

53 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
autism spectrum disorder3MONDO:0005258EFO:0003756
dystocia3MONDO:0006737EFO:1000911
alcohol abuse3MONDO:0002046MONDO:0007079
benign muscle neoplasm3MONDO:0003061MONDO:0003061
alcohol withdrawal2MONDO:0005433EFO:0004777
autism2MONDO:0005260EFO:0003758
cocaine dependence2MONDO:0005186EFO:0002610
neuralgia2MONDO:0021667EFO:0005762
post-traumatic stress disorder2MONDO:0005146EFO:0001358
obesity disorder2MONDO:0011122EFO:0001073
physiological sexual disorder2MONDO:0002134EFO:0004714
obsessive-compulsive disorder2MONDO:0008114EFO:0004242
mood disorder2MONDO:0005371EFO:0004247
ductal breast carcinoma in situ2MONDO:0005023EFO:0000432
myocardial infarction2MONDO:0005068EFO:0000612
obstructive sleep apnea syndrome2MONDO:0007147EFO:0003918
postmenopausal atrophic vaginitis2MONDO:0001410EFO:1001271
social phobia2MONDO:0001247EFO:1001917
depressive disorder2MONDO:0002050MONDO:0002050
substance-related disorder2MONDO:0002494MONDO:0002491
osteoarthritis, knee2MONDO:0005416EFO:0004616
psychiatric disorder2MONDO:0002025MONDO:0002025
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
Prader-Willi syndrome2MONDO:0008300MONDO:0008300
fragile X syndrome2MONDO:0010383MONDO:0010383
frontotemporal dementia2MONDO:0017276MONDO:0017276
drug dependence2MONDO:0005303EFO:0003890
eating disorder2MONDO:0005451EFO:0005203
osteoarthritis2MONDO:0005178MONDO:0005178
opiate dependence1MONDO:0005530EFO:0005611
sleep apnea syndrome1MONDO:0005296EFO:0003877
schizoaffective disorder1MONDO:0005487EFO:0005411
neurodevelopmental disorder1MONDO:0700092EFO:0010642
major depressive disorder1MONDO:0002009MONDO:0002009
diabetes insipidus1MONDO:0004782MONDO:0004782
preeclampsia0MONDO:0005081EFO:0000668
gastroparesis0MONDO:0006769EFO:1000948
attention deficit-hyperactivity disorder0MONDO:0007743EFO:0003888
anorexia nervosa0MONDO:0005351MONDO:0005351

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 504.

Phase distribution

PhaseTrials
Not specified209
PHASE295
PHASE468
PHASE143
PHASE334
EARLY_PHASE133
PHASE2/PHASE311
PHASE1/PHASE211

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07119398PHASE4RECRUITINGOxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM
NCT07401524PHASE4RECRUITINGCarbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
NCT00200252PHASE4COMPLETEDOxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose
NCT00695331PHASE4UNKNOWNEfficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation
NCT00777166PHASE4COMPLETEDCardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia
NCT00784797PHASE4COMPLETEDMisopristol Versus Pitocin for Second Trimester Abortion
NCT00785395PHASE4COMPLETEDUp-Down Oxytocin Infusion
NCT00790062PHASE4COMPLETEDOxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
NCT00906347PHASE4COMPLETEDA Trial of Oral Misoprostol for Labor Augmentation
NCT00919802PHASE4COMPLETEDIntranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis
NCT00975416PHASE4TERMINATEDOxytocin and Cognitive Behavioral Therapy in Drug Dependence
NCT00977769PHASE4COMPLETEDCarbetocin Versus Oxytocin and Hemodynamic Effects
NCT01190163PHASE4TERMINATEDOpen Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction
NCT01216605PHASE4COMPLETEDOxytocin and Emotion Recognition
NCT01252342PHASE4WITHDRAWNDoes Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?
NCT01549223PHASE4COMPLETEDOxytocin And Uterotonic Agent Use For Cesarean Delivery
NCT01614093PHASE4COMPLETEDEffects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
NCT01631682PHASE4COMPLETEDPilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
NCT01827124PHASE4UNKNOWNRandomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption
NCT01829516PHASE4COMPLETEDIntranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers
NCT02044549PHASE4COMPLETEDCarbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
NCT02150954PHASE4COMPLETEDFoley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor
NCT02273115PHASE4COMPLETEDFoley With Oxytocin Versus Foley no Oxytocin for Induction of Labor
NCT02391636PHASE4COMPLETEDCarbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage
NCT02410655PHASE4WITHDRAWNAn Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery
NCT02485444PHASE4COMPLETEDOxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion
NCT02487797PHASE4COMPLETEDComparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation
NCT02488642PHASE4COMPLETEDMedical Management of Late Intrauterine Death.
NCT02528136PHASE4COMPLETEDThe Clinical Carbetocin Myocardium Trial
NCT02553226PHASE4COMPLETEDContinued Versus Discontinued Oxytocin Stimulation of Labour
NCT02595749PHASE4COMPLETEDEffects of Intranasal Oxytocin on Cigarette Smoking
NCT02602301PHASE4UNKNOWNThe Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels
NCT02723461PHASE4UNKNOWNContinuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor
NCT02737254PHASE4COMPLETEDOxytocin and Attachment-related Interpretation Bias
NCT02801227PHASE4UNKNOWNOxytocin vs. Prostaglandin for Induction of Labor in Primiparas With Prelabor Rupture of Membrane and Low Bishop
NCT02940574PHASE4COMPLETEDNeural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03010670PHASE4COMPLETEDOxytocin and Interpersonal Motor Resonance
NCT03140488PHASE4COMPLETEDOxytocin Dosage to Decrease Induction Duration
NCT03246919PHASE4TERMINATEDIdeal Time of Oxytocin Infusion During Cesarean Section
NCT03308643PHASE4COMPLETEDEffect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

143 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DESMOPRESSINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR1B, AVPR2, OXTR
ATOSIBANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2, OXTR
CARBETOCINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2, OXTR
MOZAVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2, OXTR
VASOPRESSINChEMBLPhase 4 (approved)AVPR1A, AVPR1B, AVPR2, OXTR
NELIVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2, OXTR
ORNIPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2, OXTR
PECAVAPTANChEMBLPhase 2AVPR1A, AVPR1B, AVPR2, OXTR
SELEPRESSINChEMBLPhase 2AVPR1A, AVPR1B, AVPR2, OXTR
LIXIVAPTANChEMBLPhase 3AVPR1A, AVPR2, OXTR
BelzutifanPubChemApprovedAVPR1A, AVPR2, OXTR
PIMOZIDEChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
RIFAMPINChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
TEGASERODChEMBL + PubChemPhase 4 (approved)AVPR1A, AVPR2
BALSALAZIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
BOSUTINIBChEMBLPhase 4 (approved)AVPR1A, AVPR2
CHLORHEXIDINEChEMBLPhase 4 (approved)AVPR1A, AVPR2
CONIVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
FLUSPIRILENEChEMBLPhase 4 (approved)AVPR1A, AVPR2
NITAZOXANIDEChEMBLPhase 4 (approved)AVPR1A, AVPR2
PYRVINIUMChEMBLPhase 4 (approved)AVPR1A, AVPR2
RIFAXIMINChEMBLPhase 4 (approved)AVPR1A, AVPR2
TOLVAPTANChEMBLPhase 4 (approved)AVPR1A, AVPR2
BALOVAPTANChEMBLPhase 3AVPR1A, AVPR2
NOLASIBANChEMBLPhase 3AVPR1A, OXTR
OTILONIUM BROMIDEChEMBLPhase 3AVPR1A, AVPR2
RETOSIBANChEMBLPhase 3AVPR2, OXTR
SEMAXANIBChEMBLPhase 3AVPR1A, OXTR
BENZETHONIUMChEMBLPhase 2AVPR1A, AVPR2
DOMIPHENChEMBLPhase 2AVPR1A, AVPR2
EPELSIBANChEMBLPhase 2AVPR2, OXTR
RELCOVAPTANChEMBLPhase 2AVPR1A, AVPR2
AbirateronePubChemApprovedAVPR1A, AVPR2
acetylcysteinePubChemApprovedAVPR1A, AVPR2
Aclidinium BromidePubChemApprovedAVPR1A, AVPR2
AcyclovirPubChemApprovedAVPR1A, AVPR2
AfatinibPubChemApprovedAVPR1A, AVPR2
AllopurinolPubChemApprovedAVPR1A, AVPR2
AlmotriptanPubChemApprovedAVPR1A, AVPR2
AlogliptinPubChemApprovedAVPR1A, AVPR2
aminolevulinic acidPubChemApprovedAVPR1A, AVPR2
AnagrelidePubChemApprovedAVPR1A, AVPR2
ApixabanPubChemApprovedAVPR1A, AVPR2
AprepitantPubChemApprovedAVPR1A, AVPR2
BosentanPubChemApprovedAVPR1A, AVPR2
ClofarabinePubChemApprovedAVPR1A, AVPR2
ClozapinePubChemApprovedAVPR1A, AVPR2
CrizotinibPubChemApprovedAVPR1A, AVPR2
DacarbazinePubChemApprovedAVPR1A, AVPR2
DesloratadinePubChemApprovedAVPR1A, AVPR2
Desoxycorticosterone PivalatePubChemApprovedAVPR1A, AVPR2
DidanosinePubChemApprovedAVPR1A, AVPR2
DihydroergotaminePubChemApprovedAVPR1A, AVPR2
ErythromycinPubChemApprovedAVPR1A, AVPR2
EthambutolPubChemApprovedAVPR1A, AVPR2
FidaxomicinPubChemApprovedAVPR1A, AVPR2
FulvestrantPubChemApprovedAVPR1A, AVPR2
GanciclovirPubChemApprovedAVPR1A, AVPR2
GefitinibPubChemApprovedAVPR1A, AVPR2
GlycopyrrolatePubChemApprovedAVPR1A, AVPR2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot